Novo Nordisk A/S has made further adjustments to its financial forecast amidst downward pressure on insulin prices in the US and a decline in market share for its glucagon-like peptide-1 (GLP-1) medicine Victoza. ---Subscribe to MedNous to access this article--- Company News
